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Abstract
Background: Atherosclerosis is a chronic disorder of the arterial wall that starts by formation of
fatty streaks and gradually evolves into atherosclerotic plaques. High-density lipoproteins (HDL)
blood levels are inversely correlated with atherosclerosis. This beneficial effect of HDL has been
partly attributed to its antioxidant properties mediated by paraoxonase1 (PON1) or platelet-
activating factor acetylhydrolase (PAF-AH). The present study was aimed to study HDL associated
enzymes i.e. PON1 and PAF-AH under experimental hypercholesterolemia and their possible
modulation on selenium (Se; an antioxidant) supplementation. Male Sprague Dawley rats were
divided into three groups and fed on the control diet, high fat diet (HFD) and HFD + Se respectively
for the period of 4 months.
Results: Cholesterol, triglycerides, HDL and LDL levels were significantly increased by HFD
feeding. Selenium supplementation lowered the triglyceride level, whereas the other lipid values
remained unchanged. Serum selenium levels were reduced by 31% and ROS levels in the liver were
2-fold increased by HFD. Se supplementation, however, diminished the HFD-induced ROS levels
by 29%. Furthermore, Se also improved the HFD-mediated reduction of serum PON1 enzyme
activity by 34% and PON1 protein levels by 21%. However, no significant effect of Se was detected
on the reduced PAF-AH proteins levels in HFD fed rats. mRNA expression of PON1 and PAF-AH
in the liver was not affected in the Se treated groups.
Conclusion: Se supplementation appears to be protective in hypercholesterolemia by restoring
the antioxidant properties of the HDL associated enzyme i.e. PON1 whereas biological system
aims towards maintaining the same PAF-AH levels even on selenium supplementation indicating its
probable role in both anti and pro-atherogenic activities. Therefore, Se supplementation might be
a valuable approach to limit the adverse effects of hypercholesterolemia and may need further
investigations.
Background
Hypercholesterolemia represents one of the important
and recognized risk factor for atherosclerosis [1]. There are
compelling evidences indicating the importance of type of
fats than the total amount of the fats with respect to the
risk of the cardiovascular diseases [2]. Cholesterol is trans-
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ported within lipoproteins in the blood stream. High den-
sity lipoprotein (HDL) cholesterol levels are inversely
related to the risk for atherosclerotic events [3] and are
found to possess anti-atherogenic activity [4]. Among the
risk factors, total cholesterol/HDL cholesterol ratio is con-
sidered to be the most predictive for atherosclerosis [5].
The protective effect of the HDL is related partly to
enzymes associated with HDL [6-8] and due to its partici-
pation in reverse cholesterol transport [9].
Paraoxonase1 (PON1) is one of the enzymes associated
with HDL [10]. PON1 was shown to protect against oxi-
dative stress [11,12], a phenomenon that can be attrib-
uted to its ability to modulate oxidized lipids in LDL and
HDL [13,14], in macrophages [15,16] and also in athero-
sclerotic plaques [17]. PON is capable of hydrolyzing
lipid peroxides in LDL [18]. Serum HDL-associated PON1
reduces oxidative stress in lipoproteins, in macrophages
and in atherosclerotic lesion, whereas PON2 acts as an
antioxidant at the cellular and not humoral level. The
attenuation to atherosclerosis is related to the nutritional
anti-oxidative induced increase in HDL-PON activity [19].
PAF-AH is the major enzyme responsible for the catabo-
lism of PAF and PAF like lipids that are also the potent
mediators of inflammation [20,21]. Genetic deficiency of
PAF-AH in defined human populations increases the
severity of atherosclerosis and other syndromes [22]. PAF-
AH has marked preference for phospholipids with short
chain moieties at syn-2 position and, with the exception
of PAF, it can equally hydrolyze oxidized phospholipids
containing at syn-2 position polyunsaturated fatty acyl
residues [23]. However, during hydrolysis the oxidized
phospholipids, PAF-AH liberate the bioactive oxidized
free fatty acids [24] and generates lysophopsphatidylcho-
line, both of which are implicated in the biological
actions of ox-LDL [25]. Thus, PAF-AH could play both
pro-atherogenic and anti-atherogenic role.
Selenium, an essential trace element, is associated with
cardiovascular diseases since years. Selenium deficiency is
related to increase in plasma cholesterol levels [26,27],
cardiac myopathy [28], other cardiovascular disease and
ischemic heart diseases [29,30]. Selenium supplementa-
tion leads to decrease in total cholesterol and triglyceride
levels [31,32].
Keeping these in view, in the present study influence of
selenium was explored on HDL associated enzymes,
PON1 and PAF-AH.
Results
Selenium levels
Selenium levels were estimated in the serum of rats from
all the groups after 4 months of diet feeding schedule (Fig-
ure 1). Significant decrease (P < 0.05) in the Se levels in
HFD group was observed in comparison to the control
group. However, an apparent increase (P < 0.001) in Se
was observed on HFD + Se (1 ppm) supplementation in
comparison to the rats fed on only HFD diet.
Lipid profile
Lipid profile analysis was done in serum (Table 1). Total
cholesterol (P < 0.001), triglycerides (P < 0.05) and HDL
cholesterol (P < 0.05) levels were found to be significantly
increased in HFD group in comparison to control group.
A highly significant increase (P < 0.001) was observed in
LDL-cholesterol and total cholesterol/HDL-cholesterol
ratio in HFD group in comparison to the control group.
However, no significant change in various lipid profile
parameters except decrease in triglycerides levels was
observed in HFD + Se group in comparison to the only
HFD fed group.
ROS (Reactive oxygen species) levels
ROS levels in liver homogenates were estimated using a
fluorescence probe DCFH-DA. Oxidation of DCFH-DA to
DCF was measured as an index of total ROS. A highly sig-
nificant (P < 0.001) increase in ROS levels was observed
in HFD group in comparison to the control group. How-
ever, a significant (P < 0.01) decrease in ROS levels were
observed in HFD+Se fed group in comparison to HFD fed
group (Figure 2).
PON1 activity
PON1 activity was estimated in serum using substrate
paraoxon. A highly significant (P < 0.001) decrease in the
level of PON1 activity was observed in HFD fed group in
comparison to control group. However, a significant (P <
0.01) increase in the level of PON1 was observed in
HFD+Se fed group in comparison to HFD fed group (Fig-
ure 3).
mRNA expression of PON1 and PAF-AH
Statistically no significant changes in the mRNA expres-
sion of PON1 and PAF-AH were observed in HFD or HFD
+ Se fed groups in comparison to the control group or
HFD fed group respectively Figure 4a, Figure 4b.
Protein expression of PON1 and PAF-AH by ELISA
PON1 protein levels were significantly (**P < 0.01)
decreased in HFD fed group in comparison to control
group. However, PON1 levels significantly (*P < 0.05)
increased in HFD + Se fed group in comparison to HFD
fed group. On the other hand, PAF-AH protein levels were
significantly (P < 0.05) decreased in HFD fed group in
comparison to the control group. However, there was no
significant change observed in HFD + Se fed group in
comparison to the HFD fed group (Table 2).Lipids in Health and Disease 2009, 8:55 http://www.lipidworld.com/content/8/1/55
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Discussion
Hypercholesterolemia represents one of the very impor-
tant and recognized risk factor for atherosclerosis [33].
Abnormally high cholesterol levels (high concentration of
LDL and low concentration of HDL) are strongly associ-
ated with the cardiovascular diseases. High cholesterol
diet leads to the cholesterol deposition in the arterial walls
[34]. Compelling evidences indicate the importance of
the type of fats than the total amount of the fats with
respect to the risk of the cardiovascular diseases [35]. Con-
trolled clinical trials have shown that replacing saturated
fats with unsaturated is more effective in lowering serum
cholesterol and reducing the risk of cardiovascular dis-
eases than simply reducing total fat consumption [36].
Selenium, an essential trace element is proved to be pro-
tective against cardiovascular diseases [37]. In the earlier
experiments in the authors laboratory, it was found that
selenium supplementation at 1 ppm level along with high
fat diet (HFD) feeding in rats inhibited the incidence of
atherosclerosis as studied by Scanning electron micros-
copy (SEM) of aorta [38]. In the present study, interest-
ingly the serum selenium levels decreased in HFD group
in comparison to the control group. On the other hand,
selenium level, as expected, increased when we gave exter-
nal supplementation of 1 ppm as sodium selenite in HFD
+ Se fed group.
Serum selenium levels Figure 1
Serum selenium levels. *P < 0.05 represents comparison between control and HFD, aaaP < 0.001 represents comparison 
between HFD and HFD + Se group.
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Excess of lipids in the serum derived from endogenous
synthesis/dietary sources initiate atherosclerosis by accu-
mulation in the cells of the arterial wall and provoking
atheroma growth [39]. In the present study, total choles-
terol and triglycerides levels were found to be significantly
increased in HFD group in comparison to control group.
Triglyceride levels were found to be greatly reduced in
HFD + Se fed group in comparison to HFD fed group.
These findings suggest the hypercholesterolemic state as
reported earlier [40-42]. The selenium potential against
hypercholesterolemia is supported by some other
research groups as well [41,43].
Table 1: Lipid profile in serum after 4 months of Control, HFD and HFD + Se feeding schedule
Lipid profile (mg/dL) Control HFD HFD + Se
Total cholesterol 71.79 ± 13.66 451.66 ± 26.73*** 438.20 ± 53.91
Triglycerides 82.50 ± 6.96 91.98 ± 0.02* 81.26 ± 11.96a
HDL-C 24.76 ± 4.26 31.70 ± 6.56* 37.58 ± 5.55
LDL-C 32.66 ± 2.81 395.52 ± 26.51*** 381.00 ± 53.58
Total cholesterol/HDL-C 2.90 ± 0.22 14.86 ± 3.86*** 11.99 ± 2.95
Data is represented as Mean ± S.D. from 5 independent observations. Data is statistically analyzed by student's t-test. **p < 0.01,*p < 0.05 
represent the comparison between control and HFD group. ap < 0.05 represents the comparison between HFD and HFD+ Se group.
Reactive oxygen species levels Figure 2
Reactive oxygen species levels. ***P < 0.001 represents comparison between control and HFD, aaP < 0.01 represents com-
parison between HFD and HFD + Se group.
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LDL has long been implicated in the development of
atherosclerosis [44]. It has also been reported that sele-
nium supplementation protect LDL from oxidation and
other atherogenic changes [45,46]. HDL has been found
to protect against the oxidation of LDL by metal ions in-
vitro [47,48] and by reverse cholesterol transport [49].
Further, LDL and HDL levels were found to be signifi-
cantly increased in HFD group in comparison to the con-
trol group. Increase in HDL levels [41,43] on Se
supplementation was also reported earlier. Moreover,
total cholesterol/HDL ratio is considered to be most pre-
dictive for atherosclerosis [48,50]. In the present study,
this ratio was found to be increased in HFD group in com-
parison to the control group suggesting greatest risk for
the clinical events related to hypercholesterolemia in HFD
group in comparison to other groups.
Reactive oxygen species (ROS) levels were estimated in
liver homogenates and were found to be increased 2-folds
in HFD group in comparison to the control group. Se sup-
plementation, however, diminished the HFD-induced
ROS levels by 29%. This suggests the presence of oxidative
stress in HFD fed group which decreased on 1 ppm sele-
nium supplementation possibly due to the anti-oxidative
property of Se. Previously also in the author's laboratory,
on analysis of glutathione peroxidase, lipid peroxidation,
nitric oxide synthase (NOS) and reduced/oxidized glu-
tathione ratio in aorta, liver and serum, it was demon-
strated that the reduced incidence of atherosclerosis on
selenium supplementation was due to the anti-oxidant
function of selenium [51,52]. Also in-vitro studies, in
author's lab, demonstrated the role of mitogen stimulated
lymphocytes and macrophage NO production on sele-
nium supplementation in HFD-induced atherogenesis in
rats [53].
Work from a number of laboratories have suggested that
the protective effect of HDL may be due to the enzymes
associated with HDL [6,48,54] i.e PON1 (Paraoxonase 1),
LCAT (Lecithin acyl transferase), PAF-AH (platelet activat-
ing factor-acetyl hydrolase)
PON1, an HDL associated enzyme, synthesized in liver,
was shown to protect against oxidative stress [11,12], a
phenomenon that can be attributed to its ability to mod-
ulated oxidized lipids in LDL and HDL [13,14], in macro-
phages [15,16] and also in atherosclerotic lesions [17]. In
the present study, biochemically, PON1 enzymes activity
was found to be significantly reduced in HFD group in
comparison to control group. In addition, protein expres-
PON1 enzyme activity Figure 3
PON1 enzyme activity. ***P < 0.001 represents comparison between control and HFD, aaP < 0.01 represents comparison 
between HFD and HFD + Se group.
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A - mRNA expression of PON1 and PAF-AH by RT-PCR. B - Densitometric analysis of PON1 and PAF-AH mRNA expression Figure 4
A - mRNA expression of PON1 and PAF-AH by RT-PCR. B - Densitometric analysis of PON1 and PAF-AH mRNA 
expression. Data is represented as Mean ± S.D. from four independent observations. Data is statistically analyzed by student's 
t-test.
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sion of PON1 by Elisa was also found to be significantly
reduced in HFD group in comparison to control group.
However, Se supplementation improved the HFD-medi-
ated reduction of serum PON1 enzyme activity by 34%
and PON1 protein levels by 21%. This suggests that oxida-
tive stress under hypercholesterolemic state leads to the
reduced activity of PON1 whereas on selenium supple-
mentation, levels started retrieving. Interestingly, the
PON1 mRNA expression studies revealed that there was
no significant change at transcriptional level. This suggests
that PON1 may possibly be involved in anti-atherogenic
activities at translational levels. In conclusion, Se supple-
mentation appears to be protective in experimental hyper-
cholesterolemia by restoring the antioxidant properties of
the HDL associated enzyme, PON1.
PAF-AH is the major enzyme responsible for the catabo-
lism of PAF (platelet activating factor). Hypercholestero-
lemia and inflammation work as partners in
atherogenesis [55,56]. Evidences have suggested that
genetic deficiency of PAF-AH in defined human popula-
tion increases the severity of atherosclerosis and other
syndromes [57]. PAF-AH possesses marked preference for
hydrolyzing oxidized phospholipids containing at syn-2
position polyunsaturated fatty acyl residues [58]. How-
ever, during hydrolysis the oxidized phospholipids, PAF-
AH liberate the bioactive oxidized free fatty acids [24] and
generates lysophopsphatidylcholine, both of which are
implicated in the biological actions of ox-LDL [25]. Thus,
PAF-AH could play both atherogenic and anti-atherogenic
role. In the present study, PAF-AH protein expression by
ELISA was found to be significantly decreased in HFD
group in comparison to control group whereas no statisti-
cally significant change was observed on selenium supple-
mentation. Interestingly, on the other hand mRNA
expression revealed that there was no significant change
in PAF-AH at the transcriptional levels. From the present
study, it is inferred that PAF-AH possibly participates in
both pro and anti-atherogenic activities as here the system
aims towards balancing the PAF-AH levels but it may need
some further investigations in order to designate the exact
role of PAF-AH.
Conclusion
In conclusion, from the results obtained by the present
study, Se supplementation appears to be protective in
experimental hypercholesterolemia by restoring the anti-
oxidative properties of the HDL associated enzyme PON1.
However, findings are inconclusive in determining the
role of PAF-AH whether pro or anti-atherogenic in role or
both and may need some further investigations. There-
fore, Se supplementation might be a valuable approach to
limit the adverse effects of hypercholesterolemia.
Materials and methods
Chemicals
Sodium selenite (Na2SeO3), 2, 3-diaminonapthalene and
Dichlorofluorescein diacetate (DCFH-DA) were pur-
chased from Sigma-Aldrich (St. Louis, Missouri, USA).
TRI-reagent and one step RT-PCR kits were obtained from
Molecular research Centre (Inc. Cincinnati, Ohio) and
QIAGEN, respectively. Antibodies against PON1 and PAF-
AH were obtained from Santa-Cruz Biotechnology, Santa
Cruz USA. All other chemicals were of analytical grade
and were procured from Indian manufacturers.
Animals
Male Sprague Dawley rats (100-150 g body weights) were
obtained from the Central Animal House, Panjab Univer-
sity, Chandigarh. The animals were kept in plastic cages
under the hygienic conditions and were fed on special
diets. Before initiating the experiment, the animals were
adapted to the laboratory conditions for a week. Neces-
sary approvals were obtained from the Institutional Ethics
Committee. The animal care and handling were done
according to the guidelines set by the World Health
Organization (WHO), Geneva, Switzerland, and the
Indian National Science Academy (INSA), New Delhi,
India.
Experimental design
Rats were divided into three groups (five animals each
group) for the present study. Group I animals served as
controls. These animals were fed on Control Diet. Group
II animals were fed on High fat Diet (HFD). Group III ani-
mals were fed on HFD with 1 ppm selenium supplemen-
tation.
Diet Preparation
Casein based diets i.e. control diet, HFD was prepared in
the laboratory itself according to the composition given
by Abraham et al [59] Table 3.
To the group III animals i.e. HFD + Se group, 1 ppm sele-
nium was given as sodium selenite and was administered
along with the high fat diet. The selenium was so chosen
that the level is in excess to adequate levels of selenium
(0.2 ppm) but well below the sub toxic limits (2.0 ppm).
Table 2: PON1 and PAF-AH levels by ELISA after 4 months of 
control, HFD and HFD + Se feeding schedule
A405 nm Control HFD HFD + Se
PON1 1.55 ± 0.13 1.06 ± 0.01** 1.28 ± 0.12a
PAF-AH 0.26 ± 0.01 0.25 ± 0.01* 0.26 ± 0.01
Data is represented as Mean ± S.D. from 5 independent observations. 
Data is statistically analyzed by student's t-test. **p < 0.01,*p < 0.05 
represent the comparison between control and HFD group. ap < 0.05 
represents the comparison between HFD and HFD+ Se group.Lipids in Health and Disease 2009, 8:55 http://www.lipidworld.com/content/8/1/55
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Selenium levels
Selenium levels were estimated in serum by fluorimetric
method[60]. The assay is based on the principle that Se
content in samples on acid digestion is converted to sele-
nous acid. The reaction between selenous acid and aro-
matic-o-diamines such as 2, 3-diaminonapathalene leads
to the formation of 4, 5- benzopiazselenol which displays
brilliant lime-green fluorescence when excited at 366 nm
in cyclohexane. Fluorescence emission in cyclohexane
extract was read on fluorescence spectrophotometer using
366 nm as excitation and 520 nm as emission wave-
lengths.
Lipid profile
Lipid profile analysis was done in serum using colorimet-
ric kits to estimate the total cholesterol, triglycerides,
HDL, LDL levels. Total Cholesterol level was estimated
using CHOP-PAP based kit (Human Diagnostic Ger-
many). Triglyceride levels were estimated using GPO
based kit (Accurex Biomedical India). HDL and LDL cho-
lesterol levels were estimated using (Fortress direct kit)
enzymatic kit.
Reactive oxygen species (ROS) levels
Determination of ROS was based on the modified
method of Driver et al [61]. Liver homogenates were pre-
pared in ice-cold Locke's buffer (154 mM NaCl, 5.6 mM
KCl, 3.6 mM NaHCO3, 2 mM CaCl2, 10 mM d-glucose
and 5 mM HEPES pH 7.4). The homogenates were
allowed to warm at 21°C for 5 min. The reaction mixture
containing 10 μM DCFH-DA and 5 mg tissue/mL was
incubated for 15 min at room temperature (21°C). After
another 30 min of incubation, the conversion of DCFH to
the fluorescent product 2, 7 dichloroflourescein (DCF)
was measured using fluorescence spectrophotometer with
excitation at 485 nm and emission at 530 nm. Back-
ground fluorescence (Conversion of DCFH-DH to DCF in
the absence of homogenate) was corrected by inclusion of
parallel blanks. The relative fluorescence intensity was
taken as the measure of amount of ROS in different
groups.
Measurement of PON1 activity
PON1 activity was assessed in serum by measuring the ini-
tial rate of Paraoxon hydrolysis to yield p-Nitrophenol at
412 nm at 25°C. The basal assay mixture included 2 mM
Paraoxon, 2 mM CaCl2 and 0.5 ml serum in 100 mM Tris/
Cl buffer. The extinction coefficient for the reaction is
18290 M-1 cm-1. Activity is expressed as μM Paraoxon
hydrolyzed/mg protein/min [62].
RNA isolation and mRNA expression of PON1 and PAF-AH 
using RT-PCR
Total RNA was isolated from fresh liver using Tri-reagent
(Molecular research Centre, Inc Ohio, USA) and the qual-
ity of isolated RNA was checked on 1.2% agarose gel elec-
trophoresis. For reverse-transcriptase polymerase chain
reaction (RT-PCR), primers for PON1, PAF-AH were
designed with the aid of software and β- actin primer was
taken from literature. The primer sequence for PON1 was
Fav- 5'-TGGCATTGGCATTTCCCTTG-3', Rev- 5'-CAG-
TAGCTTTCACTCCGGTAA-3' and for PAF-AH Fav- 5'-
CTGATGACAAGACCCTCCGTG-3', Rev- 5'-CCGTAAC-
CAGTGTGGTCCGGAT-3' and for β-actin Fav- 5'-
AGAGCTATGAGCTGCCTGAC-3', Rev-3'-CTGCATCCT-
GTCAGCCTACG-5'. After pilot experiments, it was found
that PCR products for PON1, PAF-AH were progressively
amplified till 35 cycles and hence 35 amplification cycles
Table 3: Composition of Control and High Fat diet (HFD):
Component Control Diet (weight %) High Fat diet (weight %)
Corn Starch 71.0 61.5
Casein 16.0 16.0
Groundnut Oil 8.0 0.0
Coconut Oil 0.0 15.0
Cholesterol 0.0 2.0
Sodium Cholate 0.0 0.5
Salt Mixture 4.0 4.0
Vitamin mixture 1.0 1.0
Potassium Perchlorate 0.0 25 mg/100 g B.W./rat/24 hrsLipids in Health and Disease 2009, 8:55 http://www.lipidworld.com/content/8/1/55
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were performed. The RT-PCR reaction (Qiagen kit) used a
template cDNA followed by PCR amplification with Accu
Taq DNA polymerase in the same tube. PCR products
were analysed by 1.5% agarose gel electrophoresis. Densi-
tometric analysis from six independent observations was
done by Image-J software.
PON1 and PAF-AH protein expression by ELISA
Wells were coated with 5 μg of sample for PON1 and PAF-
AH in 100 μl of 0.05 M carbonate buffer (pH 9.6) and
kept overnight at 4°C, in a moist chamber. Plates were
flicked to remove the unbound antigen solution and wells
were blocked with 1% BSA in 0.1 M phosphate buffer
saline (pH 7.2) for1 hr at 37°C. Plates were flicked and
wells were washed with 200 μl of PBS containing 0.05%
(v/v) Tween-20. Wells were then incubated with anti-
PON1 and anti-PAF-AH respectively, diluted in PBS (con-
taining 0.05% Tween and 1% BSA) and kept for 2 hr at
37°C. Plates were washed again and incubated with anti-
goat secondary antibody (peroxidase labeled) for PON1
(1:1000) and PAF-AH (1:1000) for 2 hr at 37°C. Wells
were washed further thrice as described above and color
was developed by addition of 2, 2'-azino-di (3-ethyl)-ben-
zothiozolinsulphonic acid reagent and absorbance at 405
nm was measured by ELISA reader.
Statistical Analysis
Data is represented as mean ± S.D. Statistical analysis of
the data was performed by student's T-test.
Abbreviations
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